The Huntsman Cancer Institute Bispecific Collaborative Access and Referral Network (HCI biCARE) is designed to increase patient access to bispecific antibodies (BsAbs), especially for underserved patients with multiple myeloma in rural areas of the Mountain West. We offer education and support to community health providers and affiliate networks to eliminate barriers to drug access and improve patient outcomes.
HCI biCARE focuses on these main objectives:
- Strengthening partnerships by engaging with community health care providers and affiliate partners for timely referrals and education.
- Dedicating Huntsman Cancer Institute staff to support the safe delivery of BsAbs to community health centers.
- Implementing an outpatient delivery system with a care continuum pathway to increase patient satisfaction and timely transitions to local treatment facilities.
Huntsman Cancer Institute serves a five-state region with a population of more than 10 million, including many American Indian Tribal Nations. By expanding the reach of academic cancer centers into rural communities and sharing educational resources to support multiple myeloma patients and their providers, HCI biCARE seeks to eliminate barriers to drug access, improve patient outcomes, and establish a model for broader implementation.
What Are Bispecific Antibodies?
BsAbs are a combination of two antibodies that can bind to two different targets at once. This allows them to bring cancer cells and immune cells into close proximity, which triggers the immune system to attack and destroy the cancer cells. BsAbs are being studied and are approved to treat different types of cancer, including multiple myeloma.
Learn more from the Food and Drug Administration.
Contact Us
Phone: 801-646-4488
Email: hcibicare@hci.utah.edu
Acknowledgement: This work is supported by Pfizer's grant program.